Filtered By:
Source: Thrombosis and Haemostasis
Condition: Bleeding
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 164 results found since Jan 2013.
Reduced-dose intravenous thrombolysis for acute intermediate high-risk pulmonary embolism: Rationale and design of the PEITHO-3 trial
Thromb Haemost. 2021 Sep 24. doi: 10.1055/a-1653-4699. Online ahead of print.ABSTRACTIntermediate high-risk pulmonary embolism (PE) is characterised by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent haemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of haemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International Trial (PEITHO)-3 study (EudraCT 2018-0...
Source: Thrombosis and Haemostasis - September 24, 2021 Category: Hematology Authors: Olivier Sanchez Anais Charles-Nelson Walter Ageno Stefano Barco Harald Binder Gilles Chatellier Daniel Duerschmied Klaus Empen Melanie Ferreira Philippe Girard Menno V Huisman David Jim énez Sandrine Katsahian Matija Kozak Mareike Lankeit Nicolas Menevea Source Type: research
Extended-Duration Low-intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism: Design of the HI-PRO Trial
Thromb Haemost. 2021 Sep 16. doi: 10.1055/a-1646-2244. Online ahead of print.ABSTRACTPatients with acute venous thromboembolism (VTE) in the setting of transient provoking factors are typically treated with short-term anticoagulation. However, the risk of recurrence may be increased in the presence of enduring risk factors. In such patients, the optimal duration of treatment remains uncertain. HI-PRO is a single-center, double-blind randomized trial. Patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) following a major provoking factor, including major surgery or major trauma, who completed at least 3 month...
Source: Thrombosis and Haemostasis - September 16, 2021 Category: Hematology Authors: Behnood Bikdeli Heather Hogan Ruth Morrison John Fanikos Umberto Campia Briana Barns Mariana Pfeferman Julia Snyder Candrika Khairani Samuel Z Goldhaber Gregory Piazza Source Type: research
Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study
CONCLUSIONS: Although the non-randomized nature of the study is prone to bias, anticoagulation with VKA was not associated with decreased thromboembolic risk, but associated with increased risk of major bleeding and may be net-harmful to patients with AF on HD.PMID:34418291 | DOI:10.1111/jth.15508
Source: Thrombosis and Haemostasis - August 21, 2021 Category: Hematology Authors: Oliver K önigsbrügge Hannah Meisel Aljoscha Beyer Sabine Schmaldienst Renate Klauser-Braun Matthias Lorenz Martin Auinger Josef Kletzmayr Manfred Hecking Wolfgang C Winkelmayer Irene Lang Ingrid Pabinger Marcus S äemann Cihan Ay Source Type: research
Oral anticoagulant use in patients with morbid obesity: A systematic review and meta-analysis
CONCLUSIONS: Patients with morbid obesity on DOACs had similar risks of stroke/systemic embolism, lower rates of recurrent VTE and major bleeding events compared to those on VKAs. However, the certainty of evidence was low given that studies were mostly observational with high risk of confounding.PMID:34399433 | DOI:10.1055/a-1588-9155
Source: Thrombosis and Haemostasis - August 16, 2021 Category: Hematology Authors: Tzu-Fei Wang Marc Carrier Karine Fournier Deborah M Siegal Gr égoire Le Gal Aur élien Delluc Source Type: research
Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine: COMMENT: COMMENT from Gruel et al.: RESPONSE from Kahn et al
J Thromb Haemost. 2021 Jul 17. doi: 10.1111/jth.15467. Online ahead of print.ABSTRACTWe acknowledge the commentary of Gruel et al. on our recent letter [1] and are pleased that the authors agree that IdeS may be a potential treatment option for the rare but potentially severe IgG-mediated platelet activation observed in complications to vaccination with ChAdOx1 nCoV-19. It is apparent that our respective but distinct expertise with regard to IdeS has led us to develop this hypothesis in parallel. As we clearly cited in our original letter these authors have previously contributed important evidence that IdeS may be benefic...
Source: Thrombosis and Haemostasis - July 17, 2021 Category: Hematology Authors: Fredrik Kahn Oongh Shannon Lars Bj örck Source Type: research
Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry
CONCLUSIONS: Patients who discontinued (n=3,114, 13.0%) had a higher risk (Hazard ratio [95% CI]) of all-cause death (1.62 [1.25-2.09]), stroke/systemic embolism (SE) (2.21 [1.42-3.44]) and myocardial infarction (MI) (1.85 [1.09-3.13]) than patients who did not, whether OAC was restarted or not. This higher risk of outcomes after discontinuation was similar for patients treated with vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) (p for interactions range=0.145-0.778). Bleeding history (1.43 [1.14-1.80]), paroxysmal vs. persistent AF (1.15 [1.02-1.29]), emergency room care setting vs. office (1.37 [1.18-...
Source: Thrombosis and Haemostasis - June 1, 2021 Category: Hematology Authors: Frank Cools Dana Johnson A John Camm Jean-Pierre Bassand Freek W A Verheugt Shu Yang Anastasios Tsiatis David A Fitzmaurice Samuel Z Goldhaber Gloria Kayani Shinya Goto Sylvia Haas Frank Misselwitz Alexander G G Turpie Keith A A Fox Karen S Pieper Ajay K Source Type: research
Adherence to the 'Atrial Fibrillation Better Care' (ABC) Pathway in Patients with Atrial Fibrillation
CONCLUSION: Adherence to the ABC pathway was suboptimal, being adopted in 1 in every 5 patients. Adherence to the ABC pathway was associated with a reduction in the risk of major adverse outcomes.PMID:34020488 | DOI:10.1055/a-1515-9630
Source: Thrombosis and Haemostasis - May 21, 2021 Category: Hematology Authors: Giulio Francesco Romiti Daniele Pastori Jos é Miguel Rivera-Caravaca Wern Yew Ding Ying X Gue Danilo Menichelli Jakub Gumprecht Monika Koziel Pil-Sung Yang Yutao Guo Gregory Yh Lip Marco Proietti Source Type: research
Optimal tests to minimise bleeding and ischaemic complications in patients on short-term mechanical circulatory support
Thromb Haemost. 2021 May 13. doi: 10.1055/a-1508-8230. Online ahead of print.ABSTRACTPatients receiving left-sided mechanical circulatory support (MCS) require systemic anticoagulation with unfractionated heparin (UFH) to prevent clotting of the circuit and reduce the risk of arterial thrombosis. With MCS, there is a very high frequency of bleeding and ischaemic complications, including stroke and systemic embolism. Monitoring of UFH can be very challenging. Whilst most centres routinely monitor the activated clotting time, prothrombin time, activated partial thromboplastin time (aPTT) and fibrinogen to assess haemostasis,...
Source: Thrombosis and Haemostasis - May 13, 2021 Category: Hematology Authors: Rahim Kanji Christophe Vandenbriele Deepa Arachchillage Susanna Price Diana Adrienne Gorog Source Type: research
